Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 18/20 | 1.00 |
| ▸ | CCNH | P51946 | 17/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 4/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | CDK9 | P50750 | 2/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 2/20 | 1.00 |
| ▸ | CDK13 | Q14004 | 2/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | CCNK | O75909 | 1/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 1/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 1/20 | 1.00 |
| ▸ | CDK8 | P49336 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434968 | 1.00 | CDK7 (1.00) | CDK7CCNHCDK5CDK5R1CDK1 | |
| SCHEMBL23682983 | 1.00 | CDK7 (1.00) | CDK7CCNHCDK5CDK5R1CDK1 | |
| SCHEMBL18229934 | 1.00 | CDK7 (1.00) | CDK7CCNHCDK5CDK5R1CDK1 | |
| SCHEMBL29355500 | 1.00 | CDK7 (1.00) | CDK7CCNHCDK5CDK5R1CDK1 | |
| Hydrochloric Acid SCHEMBL29867414 | 0.99 | CDK7 (0.99) | CDK7CCNHCDK5CDK5R1CDK1 | |
| SCHEMBL18313531 | 0.95 | CDK7 (0.94) | CDK7CCNHCDK5CDK5R1CDK1 | |
| SCHEMBL30337868 | 0.95 | CDK7 (1.00) | CDK7CCNHCDK5CDK5R1CDK1 | |
| SCHEMBL18313553 | 0.95 | CDK7 (1.00) | CDK7CCNHCDK5CDK5R1CDK1 | |
| SCHEMBL29355486 | 0.95 | CDK7 (1.00) | CDK7CCNHCDK5CDK5R1CDK1 | |
| SCHEMBL18313499 | 0.95 | CDK7 (1.00) | CDK7CCNHCDK5CDK5R1CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023009833-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-23 | — | — | WO | disclosed |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230114207-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20210300911-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2021133601-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021121390-A1 | HETEROCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND APPLICATION THEREOF | 苏州信诺维医药科技股份有限公司 | 2021-06-24 | — | — | WO | disclosed |
| CN-112716957-A | Application of CDK7 targeted inhibitor in preparation of medicine for treating cytokine release syndrome caused by CAR-T treatment | 复旦大学附属肿瘤医院 | 2021-04-30 | — | — | CN | disclosed |
| US-10981903-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20180135134-A1 | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH CORTISTATIN DERIVATIVES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-17 | — | — | US | disclosed |
| EP-3294418-A1 | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH CORTISTATIN DERIVATIVES | President and Fellows of Harvard College (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2017142621-A1 | CORTISTATIN ANALOGS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017112823-A1 | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH SPECIFIC CORTISTATIN DERIVATIVES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112815-A1 | CORTISTATIN ANALOGS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| WO-2016182904-A1 | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH CORTISTATIN DERIVATIVES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-11-17 | — | — | WO | disclosed |
| US-9382239-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140309249-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | Dana-Farber Cancer Intitute, Inc. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2013074986-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981903-B2 | Inhibitors of c-Jun-N-terminal kinase (JNK) | CNKSR1, MAPK1, MAP3K1 | CDK7 129/4885CCNH 292/4885CDK5 62/4885 |
| US-20210300911-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | CDK7 129/4885CCNH 292/4885CDK5 62/4885 |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | CDK7 2189/4885CCNH 2179/4885CDK5 213/4885 |
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | CDK7 129/4885CCNH 292/4885CDK5 62/4885 |
| US-20160368910-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | CDK7 129/4885CCNH 292/4885CDK5 62/4885 |
| US-20140309249-A1 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | CDK7 129/4885CCNH 292/4885CDK5 62/4885 |
| US-20230114207-A1 | THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER | CDK7, CDC7, CDK8 | CDK7 1/4885CCNH 45/4885CDK5 18/4885 |
| US-20180135134-A1 | TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH CORTISTATIN DERIVATIVES | RUNX1, CTTN, CBFB | CDK7 2638/4885CCNH 2281/4885CDK5 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.